Dataset related to article "Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer."

<p><strong>Aim:</strong> The association of tyrosine kinase inhibitors (TKIs) and local radiotherapy in <em>EGFR</em>-mutated non-small-cell lung cancer patients experiencing disease progression under TKIs could be a valid an option. <strong>Patients &amp; methods:</strong> We included 131 patients experiencing disease progression during first-line TKI. In group A, patients received TKI beyond progression and site(s) of progression were irradiated; in group B, patients remained on TKI alone beyond progression; and group C stopped TKI at first disease progression. <strong>Results:</strong> Median overall survival resulted longer in group A versus B and C (p&nbsp;&lt;&nbsp;0.0001). Group A had a trend toward a longer second progression-free survival (measured from the time of first progression until second progression) versus group B (p&nbsp;=&nbsp;0.06). <strong>Conclusion:</strong> TKI beyond progression in association with local ablative treatment is a valid treatment option in oligoprogressive patients.</p> <p>&nbsp;</p> <p>&nbsp;</p>